MBX Biosciences
173 hedge funds and large institutions have $3.06B invested in MBX Biosciences in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 49 reducing their positions, and 21 closing their positions.
95% more capital invested
Capital invested by funds: $1.57B → $3.06B (+$1.49B)
86% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 21
51% more call options, than puts
Call options by funds: $19.6M | Put options by funds: $13M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
31% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 49
10% more funds holding
Funds holding: 157 → 173 (+16)
5.98% more ownership
Funds ownership: 110.58% → 116.56% (+6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$87.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$83.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$62.4M |
| 4 |
BlackRock
New York
|
+$13.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$35.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$32.6M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$27.3M |
| 4 |
CP
Caligan Partners
New York
|
-$22.7M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.9M |
MBX Hedge Fund Activity: Q2 2026 in Review
173 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q2 2026, worth a combined $3.06B — up 95% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new MBX positions and 21 closed out — a net gain of 18 holders — while 64 added to existing stakes and 49 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $87.6M. The largest seller was Deep Track Capital, cutting an estimated $35.8M.
- 173 institutional investors held MBX Biosciences (MBX) as of Q2 2026, up from 157 in Q1 2026.
- Funds reported $3.06B of MBX Biosciences stock for Q2 2026, up 95% quarter-over-quarter.
- 39 funds opened new MBX Biosciences positions in Q2 2026 and 21 closed out, a net change of +18 holders.
- The largest MBX Biosciences buyer in Q2 2026 was Paradigm Biocapital Advisors, an estimated $87.6M added.
- The largest MBX Biosciences seller in Q2 2026 was Deep Track Capital, an estimated $35.8M sold.
Based on aggregated 13F filings for Q2 2026.